Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

2010330 citationsJournal Article

Authors

IPI-504 has clinical activity in patients with NSCLC, particularly among patients with ALK rearrangements.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 28, Issue 33, pp. 4953-4960

Field-Weighted Citation Impact: 17.57